• A
  • A
  • A

Georgios V. Georgakis, MD, PhD — Academic Profile

  • Assistant Professor of Surgery

Board Certifications

Education

MD
  • University of Athens (2002)
PhD
  • University of Athens (2013; thesis, "The Role of PI3K-AKT-mTOR Pathway in the Pathogenesis of Hodgkin's Lymphoma")
Residency Training
  • General Surgery, University of Connecticut
Fellowship Training
  • Surgical Oncology, University of Pittsburgh
  • Research, University of Texas, MD Anderson Cancer Center

Affiliated Specialty Centers

Clinical Interests/Expertise

  • Treatment and management of malignant and benign tumors of the gastrointestinal tract including liver, pancreas, esophagus, stomach, small bowel, appendix and colon, and peritoneal mesothelioma
  • Standard open surgery as well as minimally-invasive (laparoscopic and robotic) surgical techniques when possible
  • Regional perfusion therapies for treating late-stage and advanced cancers, including cytoreductive surgery with heated hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)
  • Sarcoma and melanoma, including sentinel lymph node biopsy and lymph node dissection
  • Irreversible electroporation (IRE) for pancreas tumor ablation (animation)
an image is here

Contact Information

Division of Surgical Oncology
Department of Surgery, Health Sciences Center T18-065
Stony Brook Medicine
Stony Brook, NY 11794-8191
Tel: 631-444-8086
Fax: 631-444-7871

For patient care information, including insurance participation and practice locations, click here.

  • Personal Statement
  • Honors
  • Research
  • Publications
  • Additional

Surgical oncology epitomizes the marriage of cutting-edge surgical technology and technique with high-level laboratory and clinical research. At Stony Brook, we are using the latest advances in cancer treatments, and we are constantly researching for better, more lasting, and safer therapies. Our team of experts, supported by our Cancer Center, is providing world-class, compassionate, and personalized care to our cancer patients.

  • Ludwig J. Pyrtek MD Memorial Award, Outstanding Resident in General Surgery for Clinical and Scientific Capabilities, University of Connecticut (2013-14)
  • Resident Research Competition Award, Surgery Resident Research Day, University of Connecticut (2013-14)
  • Alexander S. Onassis Public Benefit Foundation, Research Scholarship (2007-08)
  • Travel Award, 10th International Conference on Malignant Lymphoma, Lugano, Switzerland (2005)
  • Trainee Excellence Award, Alumni and Faculty Association, University of Texas, M. D. Anderson Cancer Center (2005)
  • Research Grant Award, Empeirikeion Foundation, Athens, Greece (2003-05)
  • Application of new technologies in cancer surgery. New drug development for regional perfusion therapies, including identification of molecular targets and their potential in combination with conventional chemotherapy.
  • > Click here to see abstracts/full text of Dr. Georgakis's journal articles on PubMed (National Library of Medicine).
  • Buglio D, Georgakis GV, Hanabuchi S, Arima K, Khaskhely NM, Liu YJ, Younes A. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008;112:1424-33.
  • Buglio D, Georgakis G, Younes A. Novel small-molecule therapy of Hodgkin lymphoma. Expert Rev Anticancer Ther 2007;7:735-40.
  • Gao M, Lin M, Moffitt RA, Salazar MA, Park J, Vacirca J, Huang C, Shroyer KR, Choi M, Georgakis GV, Sasson AR, Talamini MA, Kim J. Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer. Br J Cancer 2019;120:88-96.
  • Georgakis GV, Eisenberg DP, Piorkowski RJ, Macaulay WP, Jimenez RE. Effect of early enteral tube feeding on patient outcome following pancreaticoduodenectomy. Conn Med 2012;76:213-8.
  • Georgakis GV, Li Y, Younes A. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9. Br J Haematol 2006;135:68-71.
  • Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ, Younes A. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin Cancer Res 2006;12:584-90.
  • Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Mills GB, Younes A. Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol 2006;132:503-11.
  • Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Younes A. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression. Exp Hematol 2006;34:1670-9.
  • Georgakis GV, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M, Carbone A, Albert V, Younes A. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 2005;130:501-10.
  • Georgakis GV, Younes A. From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy. Expert Rev Anticancer Ther 2006;6:131-40.
  • Georgakis GV, Younes A. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond. Future Oncol 2005;1:273-81.
  • Georgakis GV, Younes A. Cytokines and lymphomas. Cancer Treat Res 2005;126:69-102.
  • Gloghini A, Buglio D, Khaskhely NM, Georgakis G, Orlowski RZ, Neelapu SS, Carbone A, Younes A. Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. Br J Haematol 2009;147:515-25.
  • Jacobs L, Burns KJ, Georgakis G. Management of major blunt liver injury at Hartford Hospital: a ten-year review. Conn Med 2013;77:159-63.
  • Luqman M, Klabunde S, Lin K, Georgakis GV, Cherukuri A, Holash J, Goldbeck C, Xu X, Kadel EE 3rd, Lee SH, Aukerman SL, Jallal B, Aziz N, Weng WK, Wierda W, O'Brien S, Younes A. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 2008;112:711-20.
  • Oki Y, Georgakis GV, Migone TS, Kwak LW, Younes A. Elevated serum BLyS levels in patients with non-Hodgkin lymphoma. Leuk Lymphoma 2007;48:1869-71.
  • Oki Y, Georgakis GV, Migone TS, Kwak LW, Younes A. Prognostic significance of serum B-lymphocyte stimulator in Hodgkin's lymphoma. Haematologica 2007;92:269-70.
  • Pagkratis S, Kryeziu S, Lin M, Hoque S, Bucobo JC, Buscaglia JM, Georgakis GV, Sasson AR, Kim J. Case report of intestinal non-rotation, heterotaxy, and polysplenia in a patient with pancreatic cancer. Medicine (Baltimore) 2017;96:e8599.
  • Rassidakis GZ, Georgakis GV, Oyarzo M, Younes A, Medeiros LJ. Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis. Mod Pathol 2004;17:946-53.
  • Rassidakis GZ, Georgakis GV, Younes A, Medeiros LJ. c-kit is not expressed in Hodgkin disease and anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma. Blood 2003;102:4619-20.
  • Valbuena JR, Rassidakis GZ, Lin P, Atwell C, Georgakis GV, Younes A, Jones D, Medeiros LJ. Expression of heat-shock protein-90 in non-Hodgkin's lymphomas. Mod Pathol 2005;18:1343-9.
  • van der Wilden GM, Velmahos GC, Emhoff T, Brancato S, Adams C, Georgakis G, Jacobs L, Gross R, Agarwal S, Burke P, Maung AA, Johnson DC, Winchell R, Gates J, Cholewczynski W, Rosenblatt M, Chang Y. Successful nonoperative management of the most severe blunt liver injuries: a multicenter study of the research consortium of new England centers for trauma. Arch Surg 2012;147:423-8.
  • Wallace CL, Georgakis GV, Eisenberg DP, Macaulay WP, Jimenez RE. Further experience with pancreatic stump closure using a reinforced staple line. Conn Med 2013;77:205-10.
  • Wolchok CL, Georgakis GV. Management of gastric cancer. In: Docimo S Jr, Pauli EM, editors. Clinical Algorithms in General Surgery. New York: Springer, 2019: 165-8.
  • Yazbeck V, Georgakis GV, Wedgwood A, Younes A. Hodgkin's lymphoma: molecular targets and novel treatment strategies. Future Oncol 2006;2:533-51.
  • Yazbeck VY, Buglio D, Georgakis GV, Li Y, Iwado E, Romaguera JE, Kondo S, Younes A. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol 2008;36:443-50.
  • Younes M, Georgakis GV, Rahmani M, Beer D, Younes A. Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma. Eur J Cancer 2006;42:542-7.
  • Zheng B, Georgakis GV, Li Y, Bharti A, McConkey D, Aggarwal BB, Younes A. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 2004;10:3207-15.
  • Zheng B, Fiumara P, Li YV, Georgakis G, Snell V, Younes M, Vauthey JN, Carbone A, Younes A. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 2003;102:1019-27.
  • > Click here to see abstracts/full text of Dr. Georgakis's journal articles on PubMed (National Library of Medicine).
  • Fellow, American College of Surgeons (FACS)
  • Memberships
  • American Association for Cancer Research
  • American College of Surgeons
  • American Medical Association
  • American Society of Clinical Oncology
  • Americas Hepato-Pancreato-Biliary Association
  • International Society of University Colon and Rectal Surgeons
  • MD Anderson Alumni & Faculty Association
  • Society for Immunotherapy for Cancer
  • Society of American Gastrointestinal and Endoscopic Surgeons
  • Society of Surgical Oncology
  • Editorial Positions
  • Journal of Surgical Oncology (Reviewer)
  • World Journal of Colorectal Surgery (Editorial Board)